EP4232046A1 - Durch trockenmahlverfahren hergestellte pharmazeutische zusammensetzungen mit celecoxib mit erhöhter auflösungsgeschwindigkeit - Google Patents
Durch trockenmahlverfahren hergestellte pharmazeutische zusammensetzungen mit celecoxib mit erhöhter auflösungsgeschwindigkeitInfo
- Publication number
- EP4232046A1 EP4232046A1 EP21803262.1A EP21803262A EP4232046A1 EP 4232046 A1 EP4232046 A1 EP 4232046A1 EP 21803262 A EP21803262 A EP 21803262A EP 4232046 A1 EP4232046 A1 EP 4232046A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- celecoxib
- composition according
- milling
- povidone
- mannitol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 title claims abstract description 135
- 229960000590 celecoxib Drugs 0.000 title claims abstract description 122
- 238000009837 dry grinding Methods 0.000 title claims abstract description 44
- 238000004090 dissolution Methods 0.000 title claims abstract description 34
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 title claims description 47
- 239000000203 mixture Substances 0.000 claims abstract description 62
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims abstract description 52
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 52
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 52
- 229940069328 povidone Drugs 0.000 claims abstract description 51
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 50
- 229930195725 Mannitol Natural products 0.000 claims abstract description 50
- 235000010355 mannitol Nutrition 0.000 claims abstract description 50
- 239000000594 mannitol Substances 0.000 claims abstract description 50
- 239000002245 particle Substances 0.000 claims abstract description 37
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 238000003801 milling Methods 0.000 claims description 64
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 52
- 229960001855 mannitol Drugs 0.000 claims description 45
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 42
- 239000000843 powder Substances 0.000 claims description 21
- 239000004094 surface-active agent Substances 0.000 claims description 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 239000012738 dissolution medium Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 4
- 239000002270 dispersing agent Substances 0.000 claims description 4
- 238000011049 filling Methods 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 description 20
- 239000002609 medium Substances 0.000 description 19
- 229940047495 celebrex Drugs 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 238000011282 treatment Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 9
- 238000007922 dissolution test Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 8
- 239000007962 solid dispersion Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 201000008482 osteoarthritis Diseases 0.000 description 7
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229960001680 ibuprofen Drugs 0.000 description 6
- 238000010951 particle size reduction Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 description 6
- 238000001878 scanning electron micrograph Methods 0.000 description 6
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 5
- 239000012064 sodium phosphate buffer Substances 0.000 description 5
- 229940001496 tribasic sodium phosphate Drugs 0.000 description 5
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 5
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000002441 X-ray diffraction Methods 0.000 description 4
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 229960001021 lactose monohydrate Drugs 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 3
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 3
- 229920002675 Polyoxyl Polymers 0.000 description 3
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 229960001259 diclofenac Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960001929 meloxicam Drugs 0.000 description 3
- 229960002009 naproxen Drugs 0.000 description 3
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 229940100688 oral solution Drugs 0.000 description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229960004380 tramadol Drugs 0.000 description 3
- 238000001238 wet grinding Methods 0.000 description 3
- 239000002023 wood Substances 0.000 description 3
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- HNUQMTZUNUBOLQ-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO HNUQMTZUNUBOLQ-UHFFFAOYSA-N 0.000 description 2
- JKXYOQDLERSFPT-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO JKXYOQDLERSFPT-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 101000656751 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 30S ribosomal protein S24e Proteins 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 2
- 239000004353 Polyethylene glycol 8000 Substances 0.000 description 2
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 2
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 2
- 208000004550 Postoperative Pain Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000005298 acute pain Diseases 0.000 description 2
- 229960000528 amlodipine Drugs 0.000 description 2
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 description 2
- 229960004005 amlodipine besylate Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 229940000425 combination drug Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229960004396 famciclovir Drugs 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 210000005095 gastrointestinal system Anatomy 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000006069 physical mixture Substances 0.000 description 2
- 229920001993 poloxamer 188 Polymers 0.000 description 2
- 229940044519 poloxamer 188 Drugs 0.000 description 2
- 229920001992 poloxamer 407 Polymers 0.000 description 2
- 229940044476 poloxamer 407 Drugs 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 229940113125 polyethylene glycol 3000 Drugs 0.000 description 2
- 229940085678 polyethylene glycol 8000 Drugs 0.000 description 2
- 235000019446 polyethylene glycol 8000 Nutrition 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229940099429 polyoxyl 40 stearate Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 2
- NWZBFJYXRGSRGD-UHFFFAOYSA-M sodium;octadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOS([O-])(=O)=O NWZBFJYXRGSRGD-UHFFFAOYSA-M 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 1
- UHIHPRCEHZQZCL-UHFFFAOYSA-N 5-(4-methylphenyl)-1-phenyl-3-(trifluoromethyl)pyrazole Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=CC=C1 UHIHPRCEHZQZCL-UHFFFAOYSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- IMWZZHHPURKASS-UHFFFAOYSA-N Metaxalone Chemical compound CC1=CC(C)=CC(OCC2OC(=O)NC2)=C1 IMWZZHHPURKASS-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920003080 Povidone K 25 Polymers 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000019069 chronic childhood arthritis Diseases 0.000 description 1
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 1
- 229960004588 cilostazol Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- 238000001523 electrospinning Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940087068 glyceryl caprylate Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000009474 hot melt extrusion Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960000509 metaxalone Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 229960003940 naproxen sodium Drugs 0.000 description 1
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 231100000628 reference dose Toxicity 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Definitions
- the invention relates to a pharmaceutical composition prepared by dry milling containing celecoxib or pharmaceutically acceptable salt or hydrate thereof, povidone, mannitol and at least one pharmaceutically acceptable excipient and the celecoxib particle size in this composition and the dissolution rate of the composition.
- Non-steroidal anti-inflammatory drugs are the most commonly prescribed drug class worldwide for the treatment of various diseases and relief of their symptoms.
- NSAIDs are non-steroidal drug class used to reduce pain and stiffness due to arthritis in diseases such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and used in the treatment of acute musculoskeletal pain, post-operative pain and dysmenorrhea.
- Celecoxib has been described in the patent numbered US5466823 with a class of 1,5-diaryl pyrazoles and their salts and processes for the preparation of such substances.
- Celebrex® is a product in oral capsule form containing celecoxib in strengths of 50 mg, 100 mg, 200 mg and 400 mg for use in the treatment of osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, acute musculoskeletal pain, chronic pain and post-operative pain.
- Concensi® is a product in tablet form containing celecoxib and amlodipine besylate providing the treatment of pain from osteoarthritis and hypertension with a combined product. It has strengths of 200 mg/2.5 mg, 200 mg/5 mg, and 200 mg/10 mg, where 200 mg of celecoxib is combined with 2.5 mg, 5 mg, and 10 mg of amlodipine besylate, respectively.
- the fixed dose combination of celecoxib-amlodipine, which was licensed in 2018, is mentioned in detail in the patent numbered US9662315B2.
- ElyxybTM is a product in oral solution form in 25 mg/mL strength, indicated for the treatment of acute migraine with or without aura.
- the celecoxib oral solution form which was developed and licensed in 2020 for celecoxib to be absorbed quickly and reach the maximum plasma concentration much faster than the Celebrex® product, is mentioned in detail in the patent numbered US9795620B2.
- celecoxib is combined with ibuprofen and this combined product can be administered by oral, rectal, intranasal, sublingual administration or by intravenous, intramuscular, intrastemal or subcutaneous injection. It has been mentioned that 25 mg to 200 mg strength of celecoxib can be combined with 50 mg to 800 mg strength of ibuprofen in this fixed dose combination.
- celecoxib may be effective in different diseases as well as its efficacy in symptomatic treatment of diseases such as osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, acute pain, and the pharmacological effect of celecoxib continues to be investigated. For this reason, it is an important need to introduce pharmaceutical celecoxib compositions will be developed for any proven indication of celecoxib, to the use of patients as innovative products with new inventions.
- NS AIDs are generally used to provide symptomatic treatment, they reduce radiological progression without increasing toxicity when used continuously in the treatment of chronic diseases such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis. For this reason, patients must take NS AIDs continuously instead of using them only to reduce the signs and symptoms of the disease.
- NSAIDs besides the benefits of NSAIDs, they have undesirable especially gastrointestinal side effects.
- the Food and Drug Administration (FDA) recommends the use of drugs at the lowest effective dose in the shortest time, in accordance with the target, in the treatments with all NSAIDs, so that patients do not encounter too many side effects while benefiting from NSAIDs.
- NSAIDs that are frequently used in the clinic are molecules in the Class 2 group of the Biopharmaceutical Classification System (BCS), with very low water solubility but high permeability.
- cryogenic spraying method creation of nano-structured amorphous drug particles with high porosity at very low temperatures
- crystalline engineering obtaining metastable polymorph, high-energy amorphous forms, ultra-thin particles by controlled crystallization process
- the mechanical particle size reduction method is the most suitable method for the industry. For this reason, there are many molecules whose particle size is reduced, and their bioavailability is increased by this method.
- wet milling method is used in order to obtain more effective and positive results in order to reduce the particle size.
- the wet milling process is a laborious and long process in the production of solid dosage forms. Because the particles produced by the wet method must be converted into solid state by a technique such as spray drying or lyophilization.
- Dry milling system can be used to facilitate the milling process, but in this case, the possibility of re-agglomeration of the milled particles arise.
- dry milling method with using excipients having function as stabilizer and surfactant is also preferred as an effective method.
- Excipients such as lactose, sorbitol, sodium lauryl sulfate, polyoxyl stearate, polyethylene glycol were used in dry milling compositions made for celecoxib in patents numbered US8808751B2 (EP2054042A1 and A4), US8735450B2, EP2421525B1, US9095496B2, US9526734B2.
- the particle size of celecoxib was reduced by milling with the mentioned excipients.
- Celecoxib is a BCS Class 2 molecule that is practically insoluble in water, is hydrophobic, and has high permeability. The very low water solubility of celecoxib results in high variation in absorption and low bioavailability after oral administration.
- celecoxib When celecoxib is taken orally in the form of capsule or tablet, it is not well absorbed, as it does not quickly distribute and dissolve in the gastrointestinal system. Therefore, it may take approximately 3 hours to reach the maximum plasma concentration following oral administration and delaying plasma concentration in this way causes the pharmacological effect to occur later. However, in cases such as migraines, acute pain, arthritis pain, dysmenorrhea, rapid pain relief effect is desired. In order to enable celecoxib to act more rapidly and to increase its bioavailability, it is necessary to improve its solubility and dissolution properties.
- the medium in which celecoxib has the highest solubility is the pH 12 medium that does not simulate any physiological medium. Therefore, the dissolution method recommended by the FDA for the Celebrex® product is pH 12 medium containing 1% sodium lauryl sulfate. In order to improve the solubility and dissolution properties of celecoxib, it is not sufficient to increase its solubility only in the pH 12 medium.
- the gastrointestinal system pH values that celecoxib will be exposed to when taken orally are in the range of pH 1.2-6.8 and its solubility in these media should also be increased.
- co-milling the hydrophobic active ingredients with hydrophilic excipients can increase the solubility more compared to milling the active ingredient alone.
- ibuprofen was milled in a planetary ball mill with excipients such as povidone, microcrystalline cellulose, hydroxypropyl methylcellulose, soluplus. Compared to ibuprofen milled alone; the solubility increased more as a result of milling ibuprofen with soluplus (Amjad Hussain et ak, Poster presentation, 2013).
- a pharmaceutical composition comprising celecoxib active substance, which is practically insoluble in water, whose solubility is increased by using the dry milling method with povidone, mannitol and at least one pharmaceutically acceptable excipient, and whose particle size is reduced to submicron size by co-milling with pharmaceutical excipients is mentioned.
- Celecoxib is a hydrophobic substance and has very low solubility and wettability in water.
- a pharmaceutical composition has been developed that will allow rapid distribution and then dissolution in the gastrointestinal tract when it is taken orally as a solid dosage form such as a tablet or capsule.
- Dry milling method which is the most suitable method for the industry, was chosen for the particle size reduction of celecoxib. However, only celecoxib was not milled in the dry milling method. By taking advantage of dry co-milling, both the milling performance of celecoxib particles were increased and the solubility increased much more than the amount that would increase depending on the particle size reduction, by means of the pharmaceutical excipients in the milling composition.
- solubility of the composition which is specified for celecoxib in the patents numbered US8808751B2 (EP2054042A1 and A4), US8735450B2, EP2421525B1, US9095496B2, US9526734B2 and obtained as a result of dry milling of celecoxib with lactose monohydrate, sodium lauryl sulfate, polyoxyl stearate, at physiological pH is considerably lower than the composition presented in the invention.
- the solubility did not increase to the same extent at the pH values in the range of pH 1.2-6.8. Therefore, the ratio by weight of povidone and mannitol presented in the invention is very critical for increasing solubility.
- the solubility of celecoxib at physiological pH values was increased.
- povidone and mannitol excipients in specific ratio in the pharmaceutical composition of celecoxib prepared by dry milling method increased the solubility at all pH physiological values in addition to pH 12 medium. It is not known in the art how or weather the ratio by weight of povidone and mannitol in the milling composition affect solubility at physiological pHs.
- the ratio by weight of povidone and mannitol in the milling composition directly affects the solubility at physiological pHs.
- the highest solute amount was obtained at 1:1:2 and 1:2:1 ratios when the milling parameters were kept constant at 500 rpm, 1 hour and 10:1 ball ratio.
- the highest solute amounts were obtained at 1 : 1 : 1, 1:1.5:1.5, 1:0.5:1.5 and 1:1.5:0.5 ratios.
- the weight ratio of celecoxib and sodium lauryl sulfate was 1 and 0.2, respectively.
- celecoxib with an average particle size of 5-10 micrometers was milled in a planetary ball mill or high-energy ball mill.
- the pharmaceutical composition obtained at the end of dry milling was dispersed in water and the particle size was measured. Since povidone, mannitol and sodium lauryl sulfate in the pharmaceutical composition dissolve very well in water, the only insoluble substance in the prepared dispersion is celecoxib. As a result of the particle size measurement, the average particle size of celecoxib was found in the range of 200 nm-1500 nm.
- solubility values were determined by preparing saturated solutions of the pharmaceutical composition prepared by dry milling from pH 1.2, pH 4.5 and pH 6.8 media containing 0.2% sodium lauryl sulfate. At the same time, the solubility values of raw celecoxib and Celebrex® were determined by preparing saturated solutions from pH 1.2, pH 4.5 and pH 6.8 media containing 0.2% sodium lauryl sulfate. Solubility values were given in Table 1.
- the developed pharmaceutical composition had a dissolution rate such that at least 40% of celecoxib was dissolved in 30 minutes in dissolution media in the range of pH 1.2-pH 6.8 containing USP Apparatus 2 (Paddle), 50 rpm rotational speed, 1000 mL, 37°C, 0.2% sodium lauryl sulfate; at least 70% of celecoxib is dissolved in 30 minutes in dissolution media in the range of pH 1.2-pH 6.8 containing 0.5% sodium lauryl sulfate.
- the dissolution profiles of the Celebrex® product and the test product were evaluated within the scope of the invention, of the dissolution test performed without maintaining the sink condition are given in Figures 7, 8 and 9.
- the dry milling method which is known and widely used in the field of pharmaceutical technology, is used not only for the purpose of reducing the particles by creating a mechanical effect, but also used as a solid dispersion preparation method in addition to the mechanical effect in the presented invention.
- methods such as spray drying, solvent evaporation, hot melt extrusion, co-precipitation, electrospinning method, lyophilization method are generally used to prepare solid dispersion.
- co-milling method is not preferred as a solid dispersion preparation method, it is the most applicable to industry.
- stable solid dispersions with increased solubility were produced by using the dry milling method.
- the developed production method is designed in way to be applied to the industry.
- the method specified in this invention is much less costly, contains less risk factors and is the most compatible with the industry than other methods applied to increase solubility known in the art.
- Celecoxib used in dry milling in the invention is in the form of crystalline form-III.
- the solid dispersion of celecoxib with povidone is prepared, the crystalline form in beginning turns into an amorphous structure. It has been stated that when a solid dispersion of amorphous celecoxib is prepared with mannitol, mannitol can induce celecoxib crystalline growth. (Bhatt V et al., 2015, International Journal of Pharmaceutics, 495/1, 132-139).
- Figure 2 SEM image of celecoxib particles in the composition obtained as a result of dry co-milled of celecoxib, povidone and sodium lauryl sulfate.
- Figure 3 SEM image of celecoxib particles in the composition obtained as a result of co-milled of celecoxib, povidone, mannitol and sodium lauryl sulfate (PVP ⁇ MAN).
- Figure 4 Dissolution rate profile of Celebrex® and the test product in the pH 1.2+0.2% SLS medium of the dissolution test by maintaining the sink condition
- Figure 5 Dissolution rate profile of Celebrex® and the test product in the pH 4.5+0.2% SLS medium of the dissolution test by maintaining the sink condition
- Figure 6 Dissolution rate profile of Celebrex® and the test product in the pH 6.8+0.2% SLS medium of the dissolution test by maintaining the sink condition
- Figure 7 Dissolution rate profile of Celebrex® and test product in the pH 1.2+0.2% SLS medium without maintaining sink condition.
- Figure 8 Dissolution rate profile of Celebrex® and test product in the pH 4.5+0.2% SLS medium without maintaining sink condition.
- Figure 9 Dissolution rate profile of Celebrex® and test product in the pH 6.8+0.2% SLS medium without maintaining sink condition.
- Figure 10 X-ray diffraction patterns of the raw celecoxib, celecoxib milled alone with dry method, and the composition obtained as a result of co-milled celecoxib and povidone.
- Figure 11 X-ray diffraction patterns of the compositions obtained as a result of co-milled celecoxib, povidone and mannitol in different weight ratios, and physical mixture of celecoxib, povidone, mannitol, and sodium lauryl sulfate.
- Invention pharmaceutical composition prepared by dry milling method containing celecoxib or its pharmaceutically acceptable salt or hydrate, povidone, mannitol and at least one pharmaceutically acceptable excipient is characterized by that celecoxib :povidone:mannitol has a weight ratio of at least 1 :0.5:0.5 and it contains celecoxib with a particle size in the range of 200 nm-1500 nm, and it has a dissolution rate such that at least 85% of celecoxib is dissolved in 30 minutes.
- the inventive pharmaceutical composition contains celecoxib in the range of 30-200 mg.
- the inventive pharmaceutical composition contains povidone in the range of 15-1000 mg.
- the inventive pharmaceutical composition contains mannitol in the range of 15-1000 mg.
- At least one pharmaceutically acceptable excipient is selected from pharmaceutically acceptable surface-active agents, colorants, fillers, lubricants and glidants, dispersants, binding agents, or excipients consisting of combinations thereof.
- At least one pharmaceutically acceptable excipient used in dry milling in the invention is preferred as sodium lauryl sulfate in surface active agent function.
- At least one of the surface-active agents such as Brij700, Brij76, Cremophor EL, lecithin, poloxamer 188, poloxamer 407, polyethylene glycol 3000, polyethylene glycol 8000, polyoxyl 40 stearate, sodium dodecyl sulfate, sodium octadecyl sulfate, Soluplus HS15, Tween 80 can also be used as surface active agent.
- croscarmellose sodium is preferred for dispersant function and magnesium stearate for lubricant function.
- the average particle size of celecoxib used in the invention is 5-10 micrometers and its crystalline structure is form-III. Since celecoxib is a hydrophobic substance, its wettability is very weak. For this reason, sodium lauryl sulfate is used in Celebrex® product to increase its wettability and solubility. Similarly, Concensi®, a celecoxib-amlodipine combined product, contains sodium lauryl sulfate in its composition. ElyxybTM, the oral solution product of celecoxib, contains glyceryl monocaprylate, polyoxyl 35 castor oil, polyoxyl 40 hydrogenated castor oil as emulsifier, and ethanol as co-solvent in its formulation.
- Ball mills were also used in the invention to reduce the particle size of celecoxib.
- Wet and dry milling can be done in planetary ball mills or high-energy ball mills. These mills can be rotated at different rotational speeds, and they can mill in the desired time. The milling speed and time vary according to the properties of the substances to be milled.
- the ratio of the amount of substance placed in the milling chamber to the weight of the ball to be used affects the milling performance. For this reason, the ball: substance ratio by weight should be at an optimum level for effective milling.
- celecoxib active ingredient was milled by using a planetary ball mill. Milling chamber of the ball mills and the balls; agate and zirconium oxide materials were chosen to minimize the interaction of celecoxib and other excipients with the milling chamber and balls.
- the main milling components and surface-active agents used in the celecoxib milling composition are given in Table 2. It can be operated at a rotational speed of 50 rpm-650 rpm in the ball mill. Speeds of 250 rpm and 500 rpm were used in the experiments presented in the invention. The milling time varies depending on the substances to be milled, but the experiments presented in the invention were made using a milling time of 1 hour to 4 hours.
- composition Components Weight Ratios of the Dissolved Amount at 120 th Substances in the Minute (mg) Composition
- the dissolved amount is higher than at 1 :0.2: 1 ratio, but still low.
- the highest dissolved amount was obtained at 1:1:2 and 1:2:1 ratio.
- the milling parameters are changed; the highest dissolved amounts were obtained at 1:1:1, 1:1.5:1.5, 1:0.5:1.5 and 1:1.5:0.5 ratios.
- the high ball: powder ratio makes it possible to obtain high solubility by using lower ratios of povidone and mannitol.
- the raito of weight of celecoxib:povidone:mannitol in the milling composition should be at least 1 :0.5:0.5.
- the solubility in water and physiological pH values increased.
- the milling composition is celecoxib:povidone: sodium lauryl sulfate (1:1:0.2)
- the dissolved amount at physiological pH is 5 mg/1000 mL (120. min) maximum
- the milling composition is celecoxib:povidone: sodium lauryl sulfate: mannitol (1 : 1 :0.2: 1)
- the dissolved amount is at least 45 mg/1000 mL (120 min).
- celecoxib:povidone:mannitol in order to increase its solubility, celecoxib:povidone:mannitol must be used in a weight ratio of at least 1:0.5:0.5 in a pharmaceutical composition prepaid by dry milling containing celecoxib, povidone, mannitol and at least one pharmaceutically acceptable excipient. It may be possible to increase the solubility by increasing this ratio, but if the ratios used in the milling composition increase, the unit weight of the pharmaceutical composition to be given to the patient will also increase. This situation may create an undesirable situation in terms of patient compliance.
- the maximum ratio determined from the experiments is 1:5:5, and in the case of using povidone and mannitol higher than this ratio, the solubility does not increase significantly and begins to decrease.
- the production method applied to prepare a pharmaceutical composition after the dry milling experiments include the following process steps;
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2020/17034A TR202017034A2 (tr) | 2020-10-26 | 2020-10-26 | Kuru öğütme yöntemi̇ i̇le hazirlanan ve çözünme hizi arttirilmiş selekoksi̇b i̇çeren farmasöti̇k kompozi̇syonlar |
PCT/TR2021/050619 WO2021230849A1 (en) | 2020-10-26 | 2021-06-17 | Pharmaceutical compositions prepared by dry milling method and containing celecoxib with increased dissolution rate |
Publications (2)
Publication Number | Publication Date |
---|---|
EP4232046A1 true EP4232046A1 (de) | 2023-08-30 |
EP4232046A4 EP4232046A4 (de) | 2023-11-08 |
Family
ID=78524739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21803262.1A Pending EP4232046A4 (de) | 2020-10-26 | 2021-06-17 | Durch trockenmahlverfahren hergestellte pharmazeutische zusammensetzungen mit celecoxib mit erhöhter auflösungsgeschwindigkeit |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP4232046A4 (de) |
TR (1) | TR202017034A2 (de) |
WO (1) | WO2021230849A1 (de) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010121328A1 (en) * | 2009-04-24 | 2010-10-28 | Iceutica Pty Ltd | A novel formulation of indomethacin |
WO2010121321A1 (en) * | 2009-04-24 | 2010-10-28 | Iceutica Pty Ltd | Method for improving the dissolution profile of a biologically active material |
CN102988296A (zh) * | 2011-09-08 | 2013-03-27 | 江苏恒瑞医药股份有限公司 | 塞来昔布固体分散体及其制备方法 |
CN110840850B (zh) * | 2018-07-24 | 2023-03-17 | 烟台药物研究所 | 一种高生物利用度的塞来昔布冻干口崩片及其制备方法 |
-
2020
- 2020-10-26 TR TR2020/17034A patent/TR202017034A2/tr unknown
-
2021
- 2021-06-17 EP EP21803262.1A patent/EP4232046A4/de active Pending
- 2021-06-17 WO PCT/TR2021/050619 patent/WO2021230849A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP4232046A4 (de) | 2023-11-08 |
WO2021230849A1 (en) | 2021-11-18 |
TR202017034A2 (tr) | 2021-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11839689B2 (en) | Formulations of enzalutamide | |
US20100233272A1 (en) | Dosage forms comprising celecoxib providing both rapid and sustained pain relief | |
JP5439182B2 (ja) | 化学物質のミセルのナノ粒子 | |
EA028009B1 (ru) | Фармацевтическая композиция с улучшенной биодоступностью | |
JP2011530532A (ja) | 固体分子分散物中のhcvプロテアーゼインヒビターの薬学的処方物 | |
US20100168247A1 (en) | Solid composites of a calcium receptor-active compound | |
KR20010054823A (ko) | 생체내이용률 향상과 개인간 및 개인내 흡수 편차를감소시킨 이트라코나졸 함유 항진균성 제제 | |
WO2006073154A1 (ja) | 医薬組成物及びその製造方法 | |
KR102290670B1 (ko) | 자가나노유화 약물전달시스템을 이용한 리바록사반의 경구용 고형제 조성물 및 이의 제조방법 | |
TWI392507B (zh) | 包埋的膠束奈米顆粒 | |
WO2021230849A1 (en) | Pharmaceutical compositions prepared by dry milling method and containing celecoxib with increased dissolution rate | |
KR102601617B1 (ko) | 비-뉴클레오시드 역전사 효소 억제제의 조성물 | |
US20040185110A1 (en) | Formulations of low solubility bioactive agents and processes for making the same | |
Lalani et al. | LIQUISOLID COMPACT APPROACH TO ENHANCE DISSOLUTION RATE OF POORLY SOLUBLE DRUGS: A RECENT RESEARCH REVIEW. | |
CA3200729A1 (en) | Pharmaceutical composition comprising meloxicam | |
Maincent | Modified release formulations manufactured by hot-melt extrusion | |
KR20230061942A (ko) | 알칼리화제를 포함하는 셀레콕시브 함유 고체분산체 및 이의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20230427 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20231010 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 9/14 20060101ALI20231004BHEP Ipc: A61K 31/415 20060101ALI20231004BHEP Ipc: A61K 31/635 20060101AFI20231004BHEP |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) |